INTRODUCTIONUnderstanding the relationship between amyloid beta (Aβ) positron emission tomography (PET) and Aβ cerebrospinal fluid (CSF) biomarkers will define their potential utility in Aβ treatment. Few population‐based or neuropathologic comparisons have been reported.METHODSParticipants 50+ years with Aβ PET and Aβ CSF biomarkers (phosphorylated tau [p‐tau]181/Aβ42, n = 505, and Aβ42/40, n = 54) were included from the Mayo Clinic Study on Aging. From these participants, an autopsy subgroup was identified (n = 47). The relationships of Aβ PET and Aβ CSF biomarkers were assessed cross‐sectionally in all participants and longitudinally in autopsy data.RESULTSCross‐sectionally, more participants were Aβ PET+ versus Aβ CSF− than Aβ PET− versus Aβ CSF+ with an incremental effect when using Aβ PET regions selected for early Aβ deposition. The sensitivity for the first detection of Thal phase ≥ 1 in longitudinal data was higher for Aβ PET (89%) than p‐tau181/Aβ42 (64%).DISCUSSIONAβ PET can detect earlier cortical Aβ deposition than Aβ CSF biomarkers. Aβ PET+ versus Aβ CSF− findings are several‐fold greater using regional Aβ PET analyses and in peri‐threshold‐standardized uptake value ratio participants.Highlights Amyloid beta (Aβ) positron emission tomography (PET) has greater sensitivity for Aβ deposition than Aβ cerebrospinal fluid (CSF) in early Aβ development. A population‐based sample of participants (n = 505) with PET and CSF tests was used. Cortical regions showing early Aβ on Aβ PET were also used in these analyses. Neuropathology was used to validate detection of Aβ by Aβ PET and Aβ CSF biomarkers.

中文翻译：

---

淀粉样蛋白 PET 比 CSF 液体生物标志物更早地检测到脑 Aβ 的沉积


引言研究β淀粉样蛋白（Aβ）正电子发射断层扫描（PET）和Aβ脑脊液（CSF）生物标志物之间的关系将定义它们在Aβ治疗中的潜在用途。很少有基于人群或神经病理学的比较报道。方法具有 Aβ PET 和 Aβ CSF 生物标志物 （磷酸化 tau [p-tau] 181/Aβ42，n = 505 和 Aβ42/40，n = 54） 的 50+ 岁参与者来自梅奥诊所衰老研究。从这些参与者中，确定了一个尸检亚组 （n = 47）。在所有参与者中对 Aβ PET 和 Aβ CSF 生物标志物的关系进行横断面评估，并在尸检数据中纵向评估。结果总体横截面上，Aβ PET+ 与 Aβ CSF− 的参与者多于 Aβ PET− 与 Aβ CSF+，当使用选择用于早期 Aβ 沉积的 Aβ PET 区域时，效果呈递增。在纵向数据中首次检测到 Thal 期 ≥ 1 的敏感性 Aβ PET （89%） 高于 p-tau181/Aβ42 （64%）。讨论A β PET 可以比 Aβ CSF 生物标志物更早地检测到皮质 Aβ 沉积。使用区域 Aβ PET 分析和阈值周标准化摄取值比参与者，Aβ PET+ 与 Aβ CSF− 的结果要高出几倍。亮点 在 Aβ 发育早期，β 淀粉样蛋白 （Aβ） 正电子发射断层扫描 （PET） 对 Aβ 沉积的敏感性高于 Aβ 脑脊液 （CSF）。使用基于 PET 和 CSF 测试的参与者样本 （n = 505）。在这些分析中，还使用了在 Aβ PET 上显示早期 Aβ 的皮质区域。神经病理学用于验证 Aβ PET 和 Aβ CSF 生物标志物对 Aβ 的检测。